On Friday, Oppenheimer reiterated its Outperform rating on Incyte (NASDAQ:INCY) with a steady price target of $82.00. According to InvestingPro data, the stock, currently trading at $69.01, appears undervalued based on its Fair Value analysis, with 8 analysts recently revising their earnings expectations upward for the upcoming period.
The firm's optimism for Incyte's future remains intact despite the clinical termination of the ALK2 inhibitor zilurgisertib in Myelofibrosis (MF). The LIMBER program updates, including Phase 1 data of BET inhibitor INCB057643, were highlighted as part of the company's clinical progress following their presentations at the American Society of Hematology (ASH).
The analyst expressed confidence in Incyte's market potential for MF treatments, especially in light of a competitor's delay. The positive developments from the LIMBER trial of BETi INCB057643 contribute to this optimistic outlook. With a market capitalization of $13.29 billion and a solid financial health score rated as GOOD by InvestingPro, the company maintains strong fundamentals to support its clinical developments. Incyte's plans to initiate a Phase 3 trial in 2025 were also noted as a significant milestone to watch.
In addition to the updates on MF treatments, Incyte reported Phase 3 registrational data for tafasitamab in relapsed or refractory Follicular Lymphoma (r/r FL). The results were promising, with the sBLA-enabling pivotal data from the inMIND study meeting its primary endpoints. The tafasitamab and lenalidomide combination (tafa+R2) demonstrated a progression-free survival (PFS) of 22.4 months compared to 13.9 months on the lenalidomide and rituximab regimen (R2) alone.
The firm anticipates that Incyte will leverage the second-line (2L) treatment opportunity for r/r FL following expected approval in the second half of 2025. The PFS improvement shown by tafasitamab over the widely used R2 regimen in the 2L setting is seen as a key advantage for Incyte in the market.
The company's impressive revenue growth of 12.94% in the last twelve months supports its expansion strategy. For deeper insights into Incyte's valuation and growth prospects, including exclusive ProTips and comprehensive analysis, check out the full research report available on InvestingPro.
In other recent news, Incyte Corporation has seen a series of significant developments. TD Cowen has lifted its price target on Incyte shares, attributing the adjustment to sales projections for povorcitinib, a drug under consideration for the treatment of hidradenitis suppurativa. Despite a pause in the Phase 2 study of INCB00262, Oppenheimer has maintained an Outperform rating for Incyte's stock. BMO Capital, however, has kept its Underperform rating, while RBC Capital Markets has reduced its price target for Incyte, both in light of the halted study.
Incyte reported a 24% increase in its third-quarter 2024 earnings, with total revenues reaching $1.14 billion. The company also announced positive top-line results from the Phase 3 study of tafasitamab for follicular lymphoma and expects substantial revenue contributions from Niktimvo, tafasitamab, and retifanlimab by 2029.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.